Familial Alzheimer's Disease (Autosomal Dominant)
What is Familial Alzheimer's Disease (Autosomal Dominant)?
Familial Alzheimer's disease is an inherited form of dementia that runs in families. It accounts for less than 5% of all Alzheimer's cases. This type starts earlier than typical Alzheimer's, often before age 65.
The condition is caused by mutations in three specific genes: APP, PSEN1, or PSEN2. When a parent carries one of these mutations, each child has a 50% chance of inheriting it. People who inherit the mutation will develop Alzheimer's disease, usually at a predictable age.
The disease affects memory, thinking, and behavior in the same ways as typical Alzheimer's. Brain cells die over time as abnormal proteins build up. These proteins include beta-amyloid plaques and tau tangles. Understanding your genetic risk helps families plan for the future and participate in research.
Symptoms
Symptoms of familial Alzheimer's disease often appear between ages 30 and 60. Early signs may be subtle and progress gradually.
- Memory loss that disrupts daily life, especially forgetting recent events
- Difficulty planning or solving problems
- Confusion with time or place
- Trouble understanding visual images and spatial relationships
- Problems with words in speaking or writing
- Misplacing things and losing the ability to retrace steps
- Decreased or poor judgment
- Withdrawal from work or social activities
- Changes in mood and personality, including depression or anxiety
- Difficulty completing familiar tasks at home or work
People with gene mutations may have no symptoms for decades before the disease begins. Blood biomarkers can detect brain changes years before memory problems start.
Concerned about Familial Alzheimer's Disease (Autosomal Dominant)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Familial Alzheimer's disease is caused by mutations in one of three genes. The APP gene provides instructions for making amyloid precursor protein. The PSEN1 and PSEN2 genes produce proteins called presenilin 1 and presenilin 2. Mutations in any of these genes cause abnormal protein processing in the brain. This leads to toxic protein buildup that damages and kills brain cells.
This condition follows an autosomal dominant inheritance pattern. This means only one copy of the mutated gene is needed to cause disease. If one parent has the mutation, each child has a 50% chance of inheriting it. The age of symptom onset is often consistent within families. Risk factors are purely genetic. Lifestyle choices do not prevent disease in mutation carriers, though they may affect progression speed.
How it's diagnosed
Diagnosis starts with a detailed family history and neurological exam. Doctors look for patterns of early-onset Alzheimer's across multiple generations. Genetic testing confirms whether you carry a mutation in APP, PSEN1, or PSEN2. This testing is usually done through specialized genetic counseling services.
Blood tests can now detect brain changes years before symptoms appear. Rite Aid offers phosphorylated tau-217 testing, a biomarker that becomes elevated in mutation carriers long before memory loss begins. This test helps track disease progression and is used in clinical trials. Brain imaging with MRI or PET scans may also be used to look for brain changes.
Treatment options
Treatment focuses on managing symptoms and maintaining quality of life. Current approaches include:
- Medications like cholinesterase inhibitors to help with memory and thinking
- Memantine to regulate brain chemical signals
- Regular physical exercise to support brain health
- Cognitive stimulation through puzzles, reading, and social activities
- Mediterranean-style diet rich in vegetables, fish, and healthy fats
- Good sleep habits to support brain waste removal
- Mental health support for depression and anxiety
- Clinical trial participation to access experimental treatments
- Genetic counseling for family planning decisions
- Care planning and legal preparation while cognition is intact
Work with a neurologist who specializes in Alzheimer's disease. Many families with genetic mutations participate in research studies. These studies test new treatments that may slow or prevent the disease.
Need testing for Familial Alzheimer's Disease (Autosomal Dominant)? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Familial Alzheimer's is caused by inherited gene mutations and starts earlier, usually before age 65. It represents less than 5% of all cases. Typical Alzheimer's develops later in life and involves multiple genetic and environmental factors. Familial cases follow a predictable pattern within families.
Genetic testing through a specialized laboratory can identify mutations in APP, PSEN1, or PSEN2 genes. This testing is usually done with genetic counseling to help you understand results. Consider testing if multiple family members developed Alzheimer's before age 65. Talk to a genetic counselor about the benefits and risks of knowing your status.
Yes, phosphorylated tau-217 becomes elevated years before memory symptoms appear in mutation carriers. This blood biomarker tracks brain changes over time. Testing is useful for clinical trial enrollment and understanding disease stage. Regular monitoring helps families prepare for future care needs.
You have a 50% chance of inheriting the mutation if one parent carries it. If you inherit the mutation, you will develop the disease unless treatments become available. If you do not inherit the mutation, your risk returns to that of the general population. Genetic testing and counseling can clarify your individual risk.
Symptom onset varies by which gene is mutated and the specific mutation. PSEN1 mutations often cause symptoms in the 40s or 50s. APP and PSEN2 mutations may start slightly later. Age of onset is often consistent within the same family.
Lifestyle changes cannot prevent the disease in people who carry mutations. However, healthy habits may influence how quickly symptoms progress. Regular exercise, good sleep, social engagement, and a healthy diet support overall brain health. Participation in clinical trials offers access to experimental preventive treatments.
Consider testing if multiple relatives developed Alzheimer's before age 65 in a pattern across generations. Genetic counseling helps you weigh the emotional, medical, and financial implications of knowing. Some people want to know for family planning or clinical trial participation. Others prefer not to know without available prevention options.
Current treatments manage symptoms but do not stop disease progression. Medications like donepezil and memantine help with memory and thinking. Clinical trials are testing drugs that may prevent or delay onset in mutation carriers. Lifestyle interventions support quality of life and may slow decline.
Testing frequency depends on your age and goals. People in clinical trials may test every 6 to 12 months to track progression. Those not yet symptomatic might test yearly or less often. Work with your neurologist to determine the right schedule. Biomarker tracking helps with care planning and trial eligibility.
Yes, many research studies focus specifically on mutation carriers. These trials often test drugs that target amyloid or tau proteins before symptoms start. Participating helps advance science and may provide access to promising treatments. The Dominantly Inherited Alzheimer Network is a major international study for families with mutations.